BBIO
BridgeBio Pharma, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 26.23K | $1.72M | n/a | −1 |
| Q2 2026 | 132 | +3 | 120.71M | $8.69B | +10 | −8 |
| Q1 2026 | 133 | +3 | 129.51M | $9.40B | +8 | −6 |
| Q4 2025 | 129 | +2 | 135.35M | $9.88B | +4 | −1 |
| Q3 2025 | 19 | -1 | 71.67M | $3.72B | n/a | −2 |
| Q2 2025 | 18 | -1 | 70.97M | $3.06B | +1 | −2 |
| Q1 2025 | 16 | +3 | 40.50M | $1.40B | +3 | n/a |
| Q4 2024 | 13 | 0 | 40.68M | $1.12B | +1 | −1 |
| Q3 2024 | 12 | -1 | 35.94M | $914.95M | n/a | −1 |
| Q2 2024 | 13 | n/a | 36.42M | $922.50M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 25.12M | n/a | $636.31M | 2.4% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.29M | n/a | $83.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 2.16M | n/a | $54.62M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 1.47M | n/a | $37.24M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | PRIMECAP Management ✦ | 926.90K | n/a | $23.48M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 893.73K | n/a | $22.64M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 824.82K | n/a | $20.89M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 565.45K | n/a | $14.32M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 548.00K | n/a | $13.88M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 241.78K | n/a | $6.12M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 224.13K | n/a | $5.68M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | AQR Capital Management ✦ | 125.16K | n/a | $3.17M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 13 | Marshall Wace ✦ | 30.85K | n/a | $781,405 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 15.30K shares, $1,136 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.28K sh · $88,980
Officer, Director · 8.72K sh · $601,868
Officer, Director · 1.80K sh · $152,436
Officer, Director · 100 sh · $8,565
Officer, Director · 8.10K sh · $679,256
Officer, Director · 1.90K sh · $154,184
Officer, Director · 17.28K sh · $1.42M
Officer, Director · 14.60K sh · $1.21M
Officer, Director · 1.20K sh · $100,444
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
4.2% of class · View original SEC filing ↗
5.0% of class · View original SEC filing ↗